Wednesday, April 06, 2022 3:05:06 PM
Moderna: Key Takeaways From Vaccine Day
Source: TipRanks
Recently, Moderna (MRNA) held its third annual vaccine day, where the company provided an update on its pipeline. While Moderna is primarily known for the outstanding success of its Covid-19 vaccine, its bulging pipeline consists of 31 vaccines in development, focusing on everything from Covid variants to the seasonal flu, to HIV and herpes. In fact, following the event, Deutsche Bank’s Emmanuel Papadakis’ main impression is that the company is “throwing the kitchen sink at infectious disease development, complementing the existing respiratory focus with a broad latent virus programme.
https://www.tipranks.com/news/article/moderna-key-takeaways-from-vaccine-day?utm_source=advfn.com&utm_medium=referral
MRNA $$$$
Source: TipRanks
Recently, Moderna (MRNA) held its third annual vaccine day, where the company provided an update on its pipeline. While Moderna is primarily known for the outstanding success of its Covid-19 vaccine, its bulging pipeline consists of 31 vaccines in development, focusing on everything from Covid variants to the seasonal flu, to HIV and herpes. In fact, following the event, Deutsche Bank’s Emmanuel Papadakis’ main impression is that the company is “throwing the kitchen sink at infectious disease development, complementing the existing respiratory focus with a broad latent virus programme.
https://www.tipranks.com/news/article/moderna-key-takeaways-from-vaccine-day?utm_source=advfn.com&utm_medium=referral
MRNA $$$$
Recent MRNA News
- Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate • ACCESS Newswire • 04/21/2026 11:01:00 PM
- Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting • ACCESS Newswire • 04/21/2026 02:00:00 PM
- Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 • ACCESS Newswire • 04/21/2026 01:40:00 PM
- Moderna to Present at Upcoming Conferences in May 2026 • ACCESS Newswire • 04/21/2026 11:00:00 AM
- Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting • ACCESS Newswire • 04/17/2026 07:00:00 PM
- Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026 • ACCESS Newswire • 04/15/2026 11:00:00 AM
- Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 • ACCESS Newswire • 04/06/2026 10:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:45:51 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/16/2026 08:32:27 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/16/2026 08:31:50 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/16/2026 08:31:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:24:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:21:25 PM
- Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute • IH Market News • 03/04/2026 11:24:49 AM
- Moderna Resolves Global Patent Litigation with Arbutus/Genevant • ACCESS Newswire • 03/03/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:14:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:10:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:04:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 02:56:47 PM
- European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 • ACCESS Newswire • 02/27/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 09:49:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 03:26:22 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/20/2026 09:03:07 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/20/2026 09:02:04 PM
- Moderna to Present at Upcoming Conferences in March 2026 • ACCESS Newswire • 02/19/2026 12:00:00 PM
